Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020
File(s)1-s2.0-S0264410X22009628-main.pdf (1.3 MB)
Published version
Author(s)
Type
Journal Article
Abstract
The number and geographic breadth of circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks
detected after the withdrawal of type 2 containing oral polio vaccine (April 2016) have exceeded fore-
casts. Using Acute Flaccid Paralysis (AFP) investigations and environmental surveillance (ES) data from
the Global Polio Laboratory Network, we summarize the epidemiology of cVDPV2 outbreaks. Between
01 January 2016 to 31 December 2020, a total of 68 unique cVDPV2 genetic emergences were detected
across 34 countries. The cVDPV2 outbreaks have been associated with 1596 acute flaccid paralysis cases
across four World Health Organization regions: 962/1596 (60.3%) cases occurred in African Region;
619/1596 (38.8%) in the Eastern Mediterranean Region; 14/1596 (0.9%) in Western-Pacific Region; and
1/1596 (0.1%) in the European Region. As the majority of the cVDPV2 outbreaks have been seeded
through monovalent type 2 oral poliovirus vaccine (mOPV2) use in outbreak responses, the introduction
of the more stable novel oral poliovirus vaccine will be instrumental in stopping emergence of new
cVDPV2 lineages
detected after the withdrawal of type 2 containing oral polio vaccine (April 2016) have exceeded fore-
casts. Using Acute Flaccid Paralysis (AFP) investigations and environmental surveillance (ES) data from
the Global Polio Laboratory Network, we summarize the epidemiology of cVDPV2 outbreaks. Between
01 January 2016 to 31 December 2020, a total of 68 unique cVDPV2 genetic emergences were detected
across 34 countries. The cVDPV2 outbreaks have been associated with 1596 acute flaccid paralysis cases
across four World Health Organization regions: 962/1596 (60.3%) cases occurred in African Region;
619/1596 (38.8%) in the Eastern Mediterranean Region; 14/1596 (0.9%) in Western-Pacific Region; and
1/1596 (0.1%) in the European Region. As the majority of the cVDPV2 outbreaks have been seeded
through monovalent type 2 oral poliovirus vaccine (mOPV2) use in outbreak responses, the introduction
of the more stable novel oral poliovirus vaccine will be instrumental in stopping emergence of new
cVDPV2 lineages
Date Issued
2023-04-06
Date Acceptance
2022-08-03
Citation
Vaccine, 2023, 41 (Supplement 1), pp.A19-A24
ISSN
0264-410X
Publisher
Elsevier BV
Start Page
A19
End Page
A24
Journal / Book Title
Vaccine
Volume
41
Issue
Supplement 1
Copyright Statement
© 2022 Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.sciencedirect.com/science/article/pii/S0264410X22009628?via%3Dihub
Publication Status
Published
Date Publish Online
2022-08-22